A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia

Kevin T. McVary, Claus Roehrborn, Emmanuel Chartier-Kastler, Mitchell Efros, Denise Bugarin, Ru Chen, Anand Patel, Cornelia Haag-Molkenteller

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Purpose We assessed the efficacy and tolerability of onabotulinumtoxinA 200 U vs placebo to treat lower urinary tract symptoms/benign prostatic hyperplasia in men previously treated with oral benign prostatic hyperplasia medication in a 24-week phase 2, multicenter, double-blind, randomized, placebo controlled, parallel group trial. Materials and Methods Patients with I-PSS (International Prostate Symptom Score) 14 or greater, peak urinary flow rate 4 to 15 ml per second and total prostate volume 30 to 80 ml were randomized 1:1 to a single intraprostatic treatment of onabotulinumtoxinA 200 U or placebo. A single-blind sham procedure followed by a 4-week run-in was included to attempt to minimize any potential placebo effect. Patients who still met eligibility criteria after the run-in entered the double-blind active treatment period. The primary end point was the change from baseline in total I-PSS at week 12. Other end points assessed at weeks 6, 12 and 24 included the change from baseline in total I-PSS, peak urinary flow rate, total prostate volume and post-void residual urine volume. Results Of 427 patients enrolled 315 were randomized and treated. Decreases from baseline in I-PSS were observed in the onabotulinumtoxinA and placebo groups (-6.3 vs -5.6 points, p <0.001) with no difference between the groups overall or in subgroups. Improvement was observed in the peak urinary flow rate, which was significant only at week 6 compared to placebo. Improvement was significant at all time points in a patient subgroup on stable concurrent α-blockers or 5α-reductase inhibitors during the study. Adverse events were similar in the 2 treatment groups. Conclusions OnabotulinumtoxinA 200 U and placebo improved I-PSS and were well tolerated but no between group difference in efficacy was observed.

Original languageEnglish (US)
Pages (from-to)150-156
Number of pages7
JournalJournal of Urology
Volume192
Issue number1
DOIs
StatePublished - Jul 2014

Keywords

  • benign prostatic hyperplasia
  • lower urinary tract symptoms
  • onabotulinumtoxinA
  • prostate
  • prostatic hyperplasia

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia'. Together they form a unique fingerprint.

  • Cite this